Celsius Holdings, Inc. Common Stock
CELH
$28.45
+4.52%
Celsius Holdings operates in the energy drink subsegment of the global non-alcoholic beverage market, owning three brands — Celsius, Alani Nu, and Rockstar Energy — while outsourcing manufacturing to third-party co-packers and distribution largely to PepsiCo, which holds an 11% stake via convertible preferred shares. The company is a high-growth challenger brand that has scaled into a multi-brand platform, with roughly 95% of revenue concentrated in North America, positioning it as a disruptive force against established players like Monster and Red Bull. The current investor narrative is dominated by a sharp deceleration in the flagship Celsius brand, which management flagged as declining, triggering an 18% single-day stock drop in August 2026 and fueling debate over whether the Alani Nu acquisition can sustainably offset core-brand weakness. Bulls point to the Alani Nu deal as a transformative multi-brand growth engine and a forward P/E near 15x as an attractive entry point, while bears highlight intensifying competition, PepsiCo's own North America volume declines, and a valuation that still demands flawless execution.…
CELH
Celsius Holdings, Inc. Common Stock
$28.45
Related headlines
Investment Opinion: Should I buy CELH Today?
The synthesized recommendation is Hold. The core thesis is that Celsius offers a high-risk, high-reward opportunity with a deeply discounted forward P/E of 15.6x and 55.4% upside to the analyst average target of $42.29, but the declining flagship brand and margin compression create substantial uncertainty. The consensus analyst rating is 'buy' with a mean of 1.75, yet the stock has fallen 53% over the past year, suggesting the market is pricing in a more bearish scenario than analysts anticipate.
Supporting evidence for a Hold includes: 1) Revenue growth of 137.7% year-over-year in Q1 2026, though acquisition-driven; 2) Forward P/E of 15.6x, a discount to Monster's historical 25-35x range; 3) Gross margin of 48.3%, down from 52.3% but still healthy for the beverage industry; 4) Free cash flow TTM of $292.8 million, positive but erratic; and 5) Implied upside of 55.4% to the average analyst target. However, the trailing P/E of 182.96x and EV/EBITDA of 54.2x indicate the stock is not cheap on current earnings, and the PEG ratio is negative due to declining earnings.
The biggest risks that could invalidate the thesis are: 1) Continued decline in the flagship Celsius brand without sufficient offset from Alani Nu; 2) Further gross margin compression below 48%; and 3) A breakdown below the 52-week low of $23.56, which could trigger a new leg lower. The rating would upgrade to Buy if the stock breaks above $35.34 (August 2026 swing high) on strong volume and gross margins stabilize above 50%, or downgrade to Sell if revenue growth turns negative or the stock breaks below $23.56. Relative to its history, the stock is undervalued on a P/S basis (4.28x vs. 54.0x in Q1 2024) but fairly valued on forward earnings given the execution risks. The valuation verdict is fairly valued with a slight undervaluation bias if the earnings recovery materializes.
Sign up to view all
CELH 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. The stock's 53% one-year decline and 5.5% proximity to its 52-week low suggest the market has already priced in significant bad news, but the declining flagship brand and margin compression are real headwinds that could persist. The 55.4% upside to the average analyst target is compelling, but the 146% spread between the low and high targets reflects deep uncertainty. A sustained recovery would require Alani Nu to continue growing at a robust pace, gross margins to stabilize above 50%, and the flagship brand to stop declining. Conversely, a breakdown below $23.56 could trigger a new leg lower. I would upgrade to bullish if the stock breaks above $35.34 on strong volume and gross margins show sequential improvement, and downgrade to bearish if revenue growth turns negative or the stock breaks below $23.56.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celsius Holdings, Inc. Common Stock's 12-month outlook, with a consensus price target around $42.29 and implied upside of +48.6% versus the current price.
Average Target
$42.29
0 analysts
Implied Upside
+48.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$26 - $64
Analyst target range
Celsius is covered by 21 analysts, a robust level of institutional interest for a mid-cap consumer stock, with a consensus recommendation of "buy" (recommendation mean of 1.75 on a 1-5 scale where 1 is Strong Buy). The average price target of $42.29 implies 55.4% upside from the current price of $27.22, a substantial gap that suggests analysts believe the recent sell-off has been overdone relative to fundamental value. The consensus leans bullish, with the recommendation mean of 1.75 indicating that the majority of analysts rate the stock a Buy or Overweight — and the institutional ratings data shows a consistent pattern of reiterations at Buy/Overweight from major firms including Citigroup, Morgan Stanley, JP Morgan, UBS, B of A Securities, and Needham throughout mid-2026, with no downgrades visible in the data. However, the persistence of these bullish ratings through a 53% one-year decline raises questions about whether analysts are anchoring to pre-sell-off valuations or genuinely see a disconnect between price and intrinsic value. The target price range is extremely wide, from a low of $26.00 to a high of $64.00 — a 146% spread between the low and high targets, which signals very high uncertainty and low conviction among the analyst community. The low target of $26.00 is just 4.5% below the current price, implying that the most bearish analyst sees essentially no upside and expects the stock to remain depressed, likely pricing in continued flagship brand erosion, margin compression, and competitive share loss. The high target of $64.00 implies 135% upside and would require a dramatic re-rating predicated on successful Alani Nu integration, a return to double-digit organic growth, margin expansion back toward the 52%+ gross margin levels of early 2025, and multiple expansion as the market regains confidence in the growth story. The estimated EPS range of $2.04 to $2.31 for the forward period is relatively tight (13% spread), suggesting analysts have reasonable confidence in the near-term earnings trajectory even if they disagree wildly on the appropriate multiple. The wide target spread, combined with the stock trading near its 52-week low and the recent 18% single-day drop, indicates that the market is in a price discovery phase where the bull and bear cases are both plausible — this is a high-risk, high-reward situation where position sizing and risk management are paramount.
Bulls vs Bears: CELH Investment Factors
The bear case currently has stronger evidence, as the flagship Celsius brand is declining, gross margins have compressed 400 basis points year-over-year, and the stock trades just 5.5% above its 52-week low after a 53% one-year decline. Bulls argue that the Alani Nu acquisition has transformed Celsius into a multi-brand platform with a forward P/E of 15.6x, but this valuation relies on an earnings recovery that has yet to materialize. The most important tension is whether Alani Nu can sustainably offset core brand weakness and drive margin expansion back toward 52%+ levels. If Alani Nu momentum fades or PepsiCo reduces support, the stock could break below $23.56 with no historical support. Conversely, if Alani Nu continues to gain share and margins stabilize, the 55% upside to analyst targets becomes achievable.
Bullish
- Alani Nu transforms growth platform: The Alani Nu acquisition drove Q1 2026 revenue to $782.6 million, a 137.7% year-over-year increase, and has successfully diversified Celsius beyond its declining flagship brand. This multi-brand strategy now includes Rockstar Energy, creating a portfolio that can compete across multiple consumer segments and distribution channels.
- Forward P/E of 15.6x is deeply discounted: Based on consensus EPS of $2.19, CELH trades at just 15.6x forward earnings, a significant discount to Monster Beverage's historical 25-35x range and below the S&P 500's forward multiple. This valuation implies the market is pricing in a permanent growth impairment, which may be overly pessimistic if Alani Nu momentum continues.
- Analyst consensus target implies 55% upside: With 21 analysts covering the stock and a consensus 'buy' rating (mean 1.75), the average price target of $42.29 represents 55.4% upside from the current $27.22. Major firms including Citigroup, Morgan Stanley, and JP Morgan have reiterated Buy/Overweight ratings throughout 2026, suggesting institutional conviction remains intact.
- Balance sheet provides downside cushion: Debt-to-equity of 0.23 and a current ratio of 1.68 indicate a conservative financial position, with $549.2 million in cash at Q1 2026. This liquidity allows Celsius to invest in marketing and innovation without immediate solvency concerns, even as free cash flow remains erratic.
Bearish
- Flagship Celsius brand is declining: Management explicitly flagged that the core Celsius brand is declining, triggering an 18% single-day stock drop on August 6, 2026. With roughly 95% of revenue concentrated in North America, the company lacks geographic diversification to offset domestic weakness, and the growth story now rests entirely on Alani Nu and Rockstar.
- Gross margin compression of 400 basis points: Gross margin fell from 52.3% in Q1 2025 to 48.3% in Q1 2026, indicating promotional intensity, input cost pressure, or an unfavorable product mix. This compression threatens the earnings recovery embedded in the 15.6x forward P/E, as consensus EPS of $2.19 assumes margin expansion that has not yet materialized.
- Erratic profitability and cash flow: Net income swung from -$61.0 million in Q3 2025 to $110.1 million in Q1 2026, while free cash flow was -$130.0 million in Q4 2025 due to a $205.9 million working capital drain. ROE of just 3.67% and ROA of 8.85% are underwhelming for a company trading at 4.28x TTM sales.
- Extreme analyst target dispersion: The target price range spans from $26.00 to $64.00, a 146% spread that signals very low conviction and high uncertainty. The low target of $26.00 is just 4.5% below the current price, implying the most bearish analyst sees essentially no upside and expects continued brand erosion.
CELH Technical Analysis
Celsius is in a sustained and severe downtrend, with the stock down 53.0% over the past year and 43.0% year-to-date, a dramatic underperformance versus the S&P 500's +16.2% 1-year return. At a current price of $27.22, the stock sits just 5.5% above its 52-week low of $23.56 and a staggering 59.2% below its 52-week high of $66.74, placing it in the bottom decile of its 52-week range — a positioning that signals persistent selling pressure and a market that has largely abandoned the growth narrative rather than a simple value opportunity. The maximum drawdown of -63.35% underscores the severity of the de-rating, and with the stock trading at only 8.5% of its 52-week range (where 0% = low, 100% = high), there is little technical evidence of a durable bottom forming. Recent momentum remains weak but shows tentative stabilization: the 1-month change of -1.45% is a modest decline that actually outperformed the S&P 500's -1.06% by a narrow margin (relative strength of -0.39%), while the 3-month change of -6.72% and 6-month change of -38.93% reveal that the bulk of the damage occurred in the first half of 2026. The divergence between the relatively flat 1-month trend and the catastrophic 6-month and 1-year trends suggests the selling may be exhausting itself, though the stock's failure to sustain the August rally from $23.77 to $35.34 — which has since given back nearly all those gains — indicates that rallies are being sold into rather than accumulated. With a beta of 0.922, the stock is slightly less volatile than the broader market on a statistical basis, but this understates the idiosyncratic risk: the 18% single-day drop on August 6, 2026, and the -63.35% max drawdown demonstrate that company-specific event risk, not market beta, is the dominant driver of volatility here. Key support sits at the 52-week low of $23.56, and a breakdown below that level would likely trigger a new leg lower with no historical price reference points to catch the fall; resistance is layered at the recent swing high of $35.34 (August 2026) and then the far more distant 52-week high of $66.74, which would require a 145% rally to reclaim. The short ratio of 2.24 days suggests short interest is moderate and not yet at capitulation levels that would fuel a violent short squeeze, meaning any recovery would likely need to be driven by fundamental improvement rather than positioning dynamics.
Beta
0.92
0.92x market volatility
Max Drawdown
-63.4%
Largest decline past year
52-Week Range
$24-$67
Price range past year
Annual Return
-50.8%
Cumulative gain past year
| Period | CELH Return | S&P 500 |
|---|---|---|
| 1m | -2.2% | -2.0% |
| 3m | -5.2% | +1.4% |
| 6m | -31.4% | +15.0% |
| 1y | -50.8% | +15.7% |
| ytd | -40.4% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELH Fundamental Analysis
Celsius's revenue trajectory has been volatile but is showing signs of deceleration at the core. Q1 2026 revenue of $782.6 million grew 137.7% year-over-year, but this massive growth rate is almost entirely attributable to the Alani Nu acquisition rather than organic expansion — the prior-year Q1 2025 revenue of $329.3 million reflects a pre-acquisition base. Sequentially, revenue has been roughly flat to slightly up: $721.6 million in Q4 2025, $725.1 million in Q3 2025, $739.3 million in Q2 2025, and $782.6 million in Q1 2026, suggesting the combined entity is growing at a low-single-digit sequential pace. The critical concern, highlighted in the August 2026 news flow, is that the flagship Celsius brand is declining, meaning the growth story now rests entirely on Alani Nu and Rockstar — a concentration risk that makes the investment case fragile if Alani Nu's momentum fades. Profitability has swung dramatically across recent quarters, reflecting both acquisition integration costs and operational volatility. Q1 2026 net income was $110.1 million (14.1% net margin) on a 48.3% gross margin, a solid result, but this followed a Q3 2025 loss of -$61.0 million (-8.4% net margin) and a Q4 2025 profit of just $24.7 million (3.4% net margin). The trailing twelve-month picture is muddied by these swings, with the trailing P/E of 182.96x reflecting the depressed TTM earnings base, while the gross margin has compressed from 52.3% in Q1 2025 to 48.3% in Q1 2026 — a 400 basis point decline that suggests either promotional intensity, input cost pressure, or a less favorable product mix. The operating margin of 18.6% is respectable for the beverage industry but has been volatile, ranging from -11.0% in Q3 2025 to 19.3% in Q2 2025, indicating limited operating leverage and high sensitivity to volume fluctuations. The balance sheet is a relative bright spot: debt-to-equity of 0.23 is conservative, the current ratio of 1.68 indicates adequate liquidity, and cash at the end of Q1 2026 stood at $549.2 million. However, free cash flow has been erratic — TTM FCF of $292.8 million is healthy, but Q4 2025 saw -$130.0 million in FCF due to a massive $205.9 million working capital drain, and Q1 2026 FCF of $65.8 million was weighed down by a $66.6 million working capital outflow. ROE of just 3.67% and ROA of 8.85% are underwhelming for a company trading at a premium valuation, and the cash flow to debt ratio of 0.03 in Q1 2026 highlights that internal cash generation is not yet robust enough to rapidly deleverage or fund aggressive growth without external financing.
Quarterly Revenue
$782615000.0B
2026-03
Revenue YoY Growth
+137.7%
YoY Comparison
Gross Margin
48.3%
Latest Quarter
Free Cash Flow
$292759000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELH Overvalued?
Because Celsius is profitable on a trailing basis (net income of $110.1 million in Q1 2026), the PE ratio is the appropriate primary metric, but the trailing P/E of 182.96x is distorted by the depressed TTM earnings base that includes the Q3 2025 loss. The forward P/E of 15.59x, based on estimated EPS of $2.19, is far more informative and reveals an enormous gap between trailing and forward multiples — the market is pricing in a dramatic earnings recovery, with forward EPS expected to be roughly 12x the trailing figure. This gap implies that analysts expect the Alani Nu integration to drive substantial margin expansion and earnings normalization, but it also means the stock is priced for a recovery that has not yet materialized, leaving little room for disappointment. On a price-to-sales basis, Celsius trades at 4.28x TTM sales and 2.80x EV/Sales, which is elevated relative to the broader Consumer Defensive sector but reflects the company's growth profile. The PEG ratio of -4.01 is not meaningful given the negative earnings growth rate in the trailing period, but the forward P/E of 15.59x compares favorably to the estimated EPS growth implied by the recovery — if Celsius delivers on the $2.19 consensus EPS, the stock would be trading at a discount to the S&P 500's forward multiple despite a superior growth trajectory. Peer comparison is challenging given the lack of explicit industry average multiples in the provided data, but contextually, Monster Beverage historically trades in the 25-35x forward P/E range, suggesting Celsius at 15.6x forward is trading at a significant discount to its closest pure-play peer — a discount that reflects the market's skepticism about the sustainability of the earnings recovery. The EV/EBITDA of 54.2x, however, tells a different story: on an enterprise value basis, Celsius is expensive relative to its current cash flows, and the price-to-free-cash-flow ratio of 29.9x (TTM) is not cheap. Historically, Celsius's valuation has compressed dramatically: the P/S ratio was 54.0x in Q1 2024, 33.6x in Q2 2024, and has fallen to 4.28x currently — a 92% compression from peak levels. The P/B ratio has fallen from 16.5x in Q1 2024 to 3.66x now, and the P/E ratio has swung from 73.7x in Q1 2024 to 182.96x (trailing) but 15.59x forward. This historical context suggests the stock has already undergone a massive de-rating and is now trading at the low end of its own historical valuation band on most metrics — which could signal either a deep value opportunity or a market that has permanently re-rated the stock lower due to structural growth concerns.
PE
183.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~153x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
54.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company's revenue growth of 137.7% in Q1 2026 is entirely acquisition-driven, masking a low-single-digit sequential growth rate and a declining flagship brand. Gross margin has compressed from 52.3% to 48.3% year-over-year, and profitability is highly volatile, with net income swinging from -$61.0 million in Q3 2025 to $110.1 million in Q1 2026. Free cash flow is erratic, including a -$130.0 million quarter in Q4 2025 due to a $205.9 million working capital drain, and ROE of 3.67% is weak for a company trading at 4.28x sales. The balance sheet is conservative with debt-to-equity of 0.23 and $549.2 million in cash, but internal cash generation is not yet robust enough to fund aggressive growth without external financing.
Market and competitive risks are elevated. The stock has a beta of 0.922, but idiosyncratic event risk is far more impactful, as evidenced by the 18% single-day drop on August 6, 2026. Valuation compression risk is high: while the forward P/E of 15.6x appears low, it is based on EPS estimates that assume a dramatic recovery from trailing EPS of $0.01. The EV/EBITDA of 54.2x and price-to-free-cash-flow of 29.9x indicate the stock is not cheap on cash flow metrics. Competitive threats are intensifying, with Monster and Red Bull aggressively defending share, and PepsiCo's own North America volume declines could lead to reduced shelf space for Celsius. Regulatory risks are minimal, but any change in distribution agreements or health regulations could impact sales.
The worst-case scenario involves a continued decline in the flagship Celsius brand, failure of Alani Nu to sustain momentum, and further gross margin erosion. This could trigger analyst downgrades and a breakdown below the 52-week low of $23.56, leading to a new leg lower with no historical support. From the current price of $27.22, a drop to the 52-week low represents a 13.5% decline, but if the stock revisits its max drawdown level of -63.35% from the 52-week high of $66.74, it could fall to around $24.46, implying a 10.1% downside. However, in a severe scenario where the stock breaks below $23.56, the next support might be around $20, representing a 26.5% loss. The analyst low target of $26.00 implies only 4.5% downside, but the wide target range and recent volatility suggest that a more severe decline is possible if fundamentals deteriorate further.
FAQ
The key risks include: 1) Brand concentration risk: The flagship Celsius brand is declining, and the growth story now relies on Alani Nu and Rockstar, which may not sustain momentum. 2) Margin compression: Gross margin fell from 52.3% to 48.3% year-over-year, threatening the earnings recovery embedded in the forward P/E. 3) Distribution risk: PepsiCo, which holds an 11% stake and is the primary distributor, reported North America volume declines, potentially leading to reduced shelf space. 4) Valuation risk: The forward P/E of 15.6x assumes a dramatic earnings recovery that has not yet materialized, leaving little room for disappointment. 5) Volatility: The stock has a max drawdown of -63.35% and experienced an 18% single-day drop in August 2026, indicating high event risk.
The 12-month forecast is divided into three scenarios. The base case (50% probability) targets a range of $32.00 to $42.29, assuming modest revenue growth and stable margins. The bull case (25% probability) targets $42.29 to $64.00, driven by successful Alani Nu integration and margin recovery. The bear case (25% probability) targets $23.56 to $26.00, assuming continued brand decline and margin erosion. The most likely scenario is the base case, where the stock trades in a range as the market awaits clearer signs of a turnaround. Key assumptions include Alani Nu growing 15-20% year-over-year and gross margins stabilizing around 48-50%.
CELH appears undervalued on a forward basis but overvalued on trailing metrics. The forward P/E of 15.6x is a significant discount to Monster Beverage's historical 25-35x range and below the S&P 500's forward multiple, suggesting the market is pricing in a permanent growth impairment. However, the trailing P/E of 182.96x and EV/EBITDA of 54.2x indicate the stock is expensive relative to current cash flows. The P/S ratio of 4.28x is down 92% from its peak of 54.0x in Q1 2024, reflecting a massive de-rating. The valuation implies the market expects the earnings recovery to be delayed or uncertain. If Celsius delivers on the consensus EPS of $2.19, the stock is undervalued; if not, it remains overvalued.
CELH presents a high-risk, high-reward opportunity that is not suitable for all investors. The stock trades at $27.22, just 5.5% above its 52-week low, with a forward P/E of 15.6x that is well below Monster Beverage's historical range. Analysts have a consensus 'buy' rating and an average target of $42.29, implying 55.4% upside. However, the flagship Celsius brand is declining, gross margins have compressed 400 basis points year-over-year, and the company faces intense competition. For risk-tolerant investors with a long-term horizon, the risk/reward may be favorable if Alani Nu continues to grow and margins stabilize. But for conservative investors, the high uncertainty and recent 53% one-year decline make it a risky bet.
CELH is more suitable for long-term investment (minimum 2-3 years) for risk-tolerant investors, given the company's early-stage turnaround and the need for sustained execution on the Alani Nu integration. The stock's beta of 0.922 suggests moderate market correlation, but idiosyncratic event risk is high, as shown by the 18% single-day drop. The dividend yield is negligible at 0.35%, so returns depend entirely on capital appreciation. Short-term trading is risky due to low earnings visibility and high volatility. A long-term horizon allows time for the flagship brand to stabilize, margins to recover, and the multi-brand strategy to prove itself. Investors should be prepared for significant drawdowns, as the stock has fallen 63.35% from its peak.